Coherus Q2: $105M Cushion Buys Time for LOQTORZI's 15% Climb

LOQTORZI sales improved, but October data remains the real test

This quarter bought Coherus time, not relief. LOQTORZI generated $13.6 million in Q2 net sales, up 15% over Q1, and the company finished the quarter with $105.3 million in cash. That runway matters, but the next real catalyst is already visible: management has pointed to a projected October disclosure as the next major checkpoint for the company's pipeline story.

Why bulls and bears are still split

The bullish case is straightforward. Sales are moving the right way, demand held up in the quarter, and the balance sheet suggests Coherus may not need to rush a financing move before October. That gives investors a chance to evaluate the next data set on its merits rather than speculate about it.

The bearish case is narrower. A one-quarter sales increase is not definitive proof of momentum, especially because management said the Q1 comparison was affected by severe weather and normal seasonality. If October data improve the clinical story, the company gains a stronger second pillar alongside commercial execution. If not, the cash cushion simply delays the next hard conversation.